Hims & Hers Surges 64.1% in 6 Months: How to Play the Stock?

Core Insights - Hims & Hers Health, Inc. (HIMS) has seen a stock increase of 64.1% over the past six months, outperforming the industry average of 23.8% and the S&P 500's gain of 20.8% [1][9] - The company has launched a new men's health category and reported strong second-quarter 2025 results, indicating growth in subscribers and online revenue [2][3] Financial Performance - Hims & Hers reported significant improvements in both top and bottom lines, with a notable increase in online revenue per average subscriber [3][10] - The company expects third-quarter 2025 revenues between $570 million and $590 million, reflecting a year-over-year increase of 42-47%, and full-year revenues between $2.3 billion and $2.4 billion, representing growth of 56-63% from 2024 levels [7][10] Market Position - Hims & Hers has outperformed competitors like Teladoc Health, Inc. and American Well Corporation, which saw stock declines of 8.5% and 14.5%, respectively, over the same period [6][9] - The company's forward 12-month price-to-sales (P/S) ratio is 4.4X, lower than the industry average of 6.1X but higher than its three-year median of 2.4X [16] Strategic Developments - Hims & Hers is expanding internationally, including the acquisition of ZAVA, which has 1.3 million active customers in Europe, and plans to enter Canada in 2026 [11][12] - The company has launched a men's health category in partnership with Marius Pharmaceuticals, introducing oral testosterone therapy to address a significant unmet need [13][14] Operational Momentum - The company has shown strong operational momentum with increased customer adoption of personalized treatment plans and higher engagement levels [10] - Management's confidence in reaffirming its full-year outlook indicates resilience in its business model and effective execution of growth strategies [10][20]